The Endocrine Society spoke out against Arkansas’ new legislation that prohibits transgender and gender diverse adolescents from accessing gender-affirming medical care. “The treatment of transgender and gender diverse youth should be governed by the best available medical evidence, not politics,” said Joshua Safer, MD, of Mount Sinai Health System in New York City and co-author of the society’s clinical practice guideline and position statement on transgender medicine.
The FDA designated the investigational once-daily oral glucokinase activator TTP399 as a “breakthrough therapy” for type 1 diabetes as adjunct to insulin, vTv Therapeutics announced.
Moms with abnormal thyrotropin levels — either high or low levels — were at increased risk for adverse pregnancy outcomes like perinatal infant death and preterm birth. (JAMA Network Open)
The Global Liver Institute, along with other organizations, penned a letter to the U.S. Preventive Services Task Force urging panel members to spotlight the link with liver diseases in the task force’s recommendations for diabetes screening.
New pooled data from the phase II and III trials on teprotumumab-trbw (Tepezza) confirmed that most patients with thyroid eye disease maintained treatment responses for up to 51 weeks after their last dose. (The Lancet Diabetes & Endocrinology)
The American Thyroid Association released new guidelines on managing anaplastic thyroid cancer, which include recommendations on nonsurgical decision-making and keeping hospice discussions in the foreground. (Thyroid)
Although DDT was banned in the U.S. almost 50 years ago, grandmothers who were exposed to this environmental pesticide may have granddaughters at great risk for obesity and early menarche. “These data suggest that the disruption of endocrine systems by DDT initiates in immature human eggs, decades before the eggs are fertilized,” said lead author Michele La Merrill, PhD, of UC Davis, in a statement. (Cancer Epidemiology, Biomarkers & Prevention)
Even people with just prediabetes often see much higher healthcare costs than those with normoglycemia. But once diagnosed with type 2 diabetes, these patients spend an average of nearly $9,000 more in healthcare costs over the subsequent 5 years. (AMA)